Drug intelligence / Profile preview

13C6-glipizide

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

13C6-glipizide is a stable isotope-labeled version of glipizide used primarily in pharmacokinetic research studies. It contains six carbon-13 isotopes in place of regular carbon-12 atoms, making it heavier but not radioactive. This labeled compound allows researchers to track drug dissolution and absorption in the gastrointestinal tract when studying modified release formulations of glipizide.

Targets

SUR1 (Sulfonylurea receptor 1)

Beyond the preview

Go deeper on 13C6-glipizide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 13C6-glipizide.

Explore the full profile